<PAGE> 1
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 1996
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period From to
_______________________________________________________
Commission File Number 1-4147
PHARMACIA & UPJOHN, INC.
(Exact name of registrant as specified in its charter)
Delaware 98-0155411
(State of incorporation) (I. R. S. Employer
Identification No.)
67 Alma Road, Windsor, Berkshire SL4 3HD United Kingdom
(Address of principal executive offices) (Zip Code)
Registrant's telephone number 44 1753 757575
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding twelve months, and (2) has been subject
to such filing requirements for the past 90 days. YES X NO
The number of shares of Common Stock, $1 Par Value, outstanding as of
November 7, 1996
was 508,095,894.
Page 1 of 23 pages
1
<PAGE> 2
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PHARMACIA & UPJOHN, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(All U.S. Dollar Amounts in Thousands, Except Per-Share Data)
<TABLE>
<CAPTION>
------------------------------------------------------------------
Unaudited
------------------------------------------------------------------
For Three Months For Nine Months
Ended September 30, Ended September 30,
--------------------------- -----------------------------
1996 1995 1996 1995
---------- ---------- ---------- ----------
<S> <C> <C> <C> <C>
Net sales $1,720,690 $1,692,726 $5,236,116 $5,144,297
Other revenue 20,533 28,799 66,538 124,039
---------- ---------- ---------- ----------
Operating revenue 1,741,223 1,721,525 5,302,654 5,268,336
Cost of products sold 533,268 466,439 1,536,480 1,457,661
Research & development 330,167 303,503 932,695 921,746
Marketing, administrative and other 539,690 636,370 1,887,223 1,913,906
Restructuring charges 37,300 - 458,200 11,804
Merger costs 15,506 1,870 66,909 1,919
---------- ---------- ---------- ----------
Operating income 285,292 313,343 421,147 961,300
Interest income 31,269 57,631 126,875 156,221
Interest expense (9,482) (24,929) (51,315) (69,932)
All other, net (2,882) (1,347) 4,905 (2,144)
---------- --------- ---------- ----------
Earnings before income taxes 304,197 344,698 501,612 1,045,445
Provision for income taxes 100,400 113,800 165,500 345,000
---------- ---------- --------- ----------
Net earnings 203,797 230,898 336,112 700,445
Dividends on preferred stock
(net of tax) 3,157 3,109 9,471 9,295
---------- ---------- ---------- ----------
Net earnings on common stock $ 200,640 $ 227,789 $ 326,641 $ 691,150
========== ========== ========== ==========
Earnings per common share:
Primary $ 0.39 $ 0.45 $ 0.64 $ 1.36
========== ========== =========== ==========
Fully diluted $ 0.39 $ 0.44 $ 0.64 $ 1.34
========== ========= =========== ==========
</TABLE>
See accompanying notes.
2
<PAGE> 3
PHARMACIA & UPJOHN, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Nine Months Ended September 30
(All U.S. dollar amounts in thousands)
<TABLE>
<CAPTION>
-----------------------------
Unaudited
-----------------------------
1996 1995
---------- ----------
<S> <C> <C>
Net cash provided by operations $ 543,697 $ 793,903
---------- ----------
Cash provided (required) by investment activities:
Acquisitions of subsidiaries (24,480) (53,006)
Additions of properties (399,823) (354,627)
Proceeds from sales of properties 15,502 37,659
Proceeds from sales of investments 1,711,496 1,303,639
Purchase of investments (1,302,999) (1,368,450)
Proceeds from the sale of discontinued operations - 11,959
Other 2,950 91,192
---------- ----------
Net cash provided (required) by investment activities 2,646 (331,634)
---------- ----------
Cash provided (required) by financing activities:
Proceeds from issuance of debt 28,349 13,295
Repayment of debt (394,551) (72,561)
Payments of ESOP debt (7,600) -
Debt maturing in three months or less (net) 498,281 (56,265)
Dividends paid to shareholders (424,531) (288,145)
Purchase of treasury stock (77,354) (102,599)
Proceeds from issuance of stock 79,821 41,792
Other 104 4,988
---------- ---------
Net cash required by financing activities (297,481) (459,495)
---------- ----------
Effect of exchange rate changes on cash 2,690 29,545
---------- ----------
Net change in cash and cash equivalents 251,552 32,319
Cash and cash equivalents, beginning of year 840,525 651,660
---------- ----------
Cash and cash equivalents, end of period $1,092,077 $ 683,979
========== ==========
</TABLE>
See accompanying notes.
3
<PAGE> 4
PHARMACIA & UPJOHN, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(All U.S. dollar amounts in thousands)
<TABLE>
<CAPTION>
----------------------------------
Unaudited
----------------------------------
September 30, December 31,
1996 1995
----------- ------------
ASSETS
<S> <C> <C>
Current assets:
Cash and cash equivalents $ 1,092,077 $ 840,525
Short-term investments 766,274 973,656
Other current assets 3,384,221 3,159,429
----------- -----------
Total current assets 5,242,572 4,973,610
----------- -----------
Long-term investments 557,867 715,348
----------- -----------
Goodwill and other intangible assets, net 1,621,791 1,722,157
----------- -----------
Properties, net 3,523,308 3,393,225
----------- -----------
Other noncurrent assets 582,174 656,261
----------- -----------
Total assets $11,527,712 $11,460,601
----------- -----------
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term debt, including current
maturities of long-term debt $ 677,766 $ 524,429
Other current liabilities 2,074,804 2,115,499
----------- -----------
Total current liabilities 2,752,570 2,639,928
----------- -----------
Long-term debt and guarantee of ESOP debt 829,731 870,308
----------- -----------
Other noncurrent liabilities 1,531,623 1,563,158
----------- -----------
Shareholders' equity:
Preferred stock, one cent par value;
authorized 100,000,000 shares; issued
Series A convertible 7,137 shares
(1995: 7,220 shares) at stated value 287,117 290,778
Common stock, one cent par value;
authorized 1,500,000,000 shares, issued
508,686,313 shares (1995: 506,625,800 shares) 5,087 5,066
Capital in excess of par value 1,551,952 1,457,240
Retained earnings 5,775,494 5,861,197
Currency translation adjustments (916,859) (986,278)
Other shareholders' equity (289,003) (240,796)
----------- -----------
Total shareholders' equity 6,413,788 6,387,207
----------- -----------
Total liabilities and shareholders' equity $11,527,712 $11,460,601
----------- -----------
</TABLE>
See accompanying notes.
4
<PAGE> 5
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED
(ALL U.S. DOLLAR AMOUNTS IN THOUSANDS, EXCEPT PER-SHARE DATA)
A - INTERIM CONSOLIDATED FINANCIAL STATEMENTS:
The consolidated financial information presented herein is unaudited, other
than the condensed consolidated balance sheet at December 31, 1995, which is
derived from audited financial statements. The interim financial statements
and notes thereto do not include all disclosures required by generally accepted
accounting principles and should be read in conjunction with the financial
statements and notes thereto included in the company's latest annual report on
Form 10-K.
In the opinion of management, the interim financial statements reflect all
adjustments of a normal recurring nature necessary for a fair statement of the
results for interim periods. The current period's results of operations are
not necessarily indicative of results that ultimately may be achieved for the
year.
Certain 1995 amounts, as presented herein, differ from amounts presented in the
quarterly financial information section of the 1995 annual report. The changes
result from the reclassification of unrealized currency hedging gains and
losses to better relate the accounting for the hedges with the underlying
transactions. Third quarter 1995 data were affected as follows: cost of
products sold decreased $27,897; marketing, administrative and other decreased
$11,717; nonoperating expense (currency exchange losses) increased $39,614.
September 30, 1995 year-to-date reclassification amounts were: cost of
products sold decreased $9,238; marketing, administrative and other decreased
$5,309; nonoperating expense increased $14,547.
B - INVENTORIES:
<TABLE>
<CAPTION>
September 30, December 31,
1996 1995
------------ ------------
<S> <C> <C>
Estimated replacement cost
(FIFO basis):
Pharmaceutical and other finished products $ 451,803 $ 487,955
Raw materials, supplies and work in process 717,530 634,250
---------- ----------
1,169,333 1,122,205
Less reduction to LIFO cost (149,709) (146,651)
---------- ----------
$1,019,624 $ 975,554
========== ==========
</TABLE>
Inventories valued on the LIFO method had an estimated replacement cost (FIFO
basis) of $393,417 at September 30, 1996, and $358,216 at December 31, 1995.
C - LITIGATION:
Various suits and claims arising in the ordinary course of business, primarily
for personal injury and property damage alleged to have been caused by the use
of the company's products, are pending against the company and its
subsidiaries. The company is also involved in several administrative and
judicial proceedings relating to environmental concerns, including actions
5
<PAGE> 6
brought by the U.S. Environmental Protection Agency and state environmental
agencies for remedial cleanup at approximately 50 sites and including site
clean-up at the company's discontinued industrial chemical operations. The
company's estimate of the ultimate cost to be incurred in connection with these
environmental situations could change due to uncertainties at many sites with
respect to potential cleanup remedies, the estimated cost of cleanup, and the
company's ultimate share of a site's cost.
Based on information currently available and the company's experience with
lawsuits of the nature of those currently filed or anticipated to be filed
which have resulted from business activities to date, the amounts accrued for
product and environmental liabilities are considered to be adequate. Although
the company cannot predict and cannot make assurances with respect to the
outcome of individual lawsuits, the ultimate liability should not have a
material effect on its consolidated financial position; and unless there is a
significant deviation from the historical pattern of resolution of such issues,
the ultimate liability should not have a material adverse effect on the
company's results of operations or liquidity.
In May 1994, the U.S. Food and Drug Administration (FDA) established a Task
Force to review the FDA's prior inspection report on Halcion, including an
assessment of the conclusions of the report, the approval of the drug, related
FDA processes and procedures, and the violation of any laws. The U.S.
Attorney's Office in Grand Rapids, Michigan assisted in this review. Several
company employees have given testimony before a grand jury sitting in the U.S.
District Court for the Western District of Michigan, and a number of current
and former employees have been interviewed by FDA and Justice Department
investigators. The Task Force recently issued its report, which found no
evidence of criminal wrongdoing, but suggested that the Justice Department is
the appropriate entity to determine and evaluate the facts and to determine
whether criminal offenses had occurred and should be pursued. The Task Force
also concluded that the evidence supports the safety and efficacy of Halcion
tablets when used in accordance with its approved labeling. However, the Task
Force recommended that a wide spectrum of experts review the safety and
efficacy data on Halcion tablets, and report their findings to the FDA's
Psychopharmalogical Drugs Advisory Committee. The Task Force also recommended
several improvements in FDA practices and procedures. The company cannot
predict the outcome of any continuing investigation by the Justice Department
or the FDA. A subcommittee of the House of Representatives has instituted a
review of some of the conclusions of the original inspection report and is
reviewing the Task Force report. The company has furnished the subcommittee a
large number of documents in responding to the subcommittee's request. The
company cannot predict the nature, scope, or timing of any further review by
the subcommittee.
The company is a party along with a number of other defendants (both
manufacturers and wholesalers) in several federal civil antitrust lawsuits,
some of which have been consolidated and transferred to Federal District Court
for the Northern District of Illinois. These suits allege that the company and
the other named defendants violated: (1) the Robinson-Patman Act by giving
substantial discounts and rebates to mail-order pharmacies and managed health
care organizations without according the same discounts to retail pharmacies,
and (2) Section I of the Sherman Antitrust Act by entering into illegal
agreements to deny such discounts and rebates to retailers. The Federal
District Court for the Northern District of Illinois certified a national class
of retail pharmacies in November 1994. In July 1996, the Federal District
Court approved a settlement between a majority of the pharmaceutical company
defendants (not including the company) and the plaintiffs in the class action
pending in the Northern District of Illinois for amounts ranging from $10,000
to $60,000. The company together with the remaining settling and non-settling
defendants, are appealing to the United States Court of Appeals for the Seventh
Circuit from certain of the trial judge's orders. Actions raising claims
similar to the federal lawsuits have been brought on behalf of retail
drugstores and/or consumers in a number of state courts, including Alabama,
Arizona, California, Colorado, the District of Columbia, Maine, Michigan,
Minnesota, New York, Washington, and Wisconsin. The California State court has
certified both a retailer class and a consumer class, and the Wisconsin State
court has certified a retailer class. In March 1996, the Federal Trade
Commission ("FTC") issued a resolution authorizing an investigation to
determine whether 22 prescription drug manufacturers, including the Company,
are engaging in unlawful concerted activities to raise, fix, maintain or
stabilize the prices of pharmaceutical drugs in the United States. In July
1996, the FTC issued document subpoenas to each of the manufacturers,
requesting pricing and marketing documents. The Company has produced documents
to the FTC in response to the subpoena.
6
<PAGE> 7
D - RESTRUCTURING CHARGES AND MERGER COSTS:
Restructuring charges of $37,300 and $458,200 in the third quarter and first
nine months of 1996, respectively, relate to actions that resulted from the
merger of Pharmacia AB and The Upjohn Company and primarily reflect accruals
for planned personnel reduction. Similar charges amounting to $91,600, were
recorded in the fourth quarter of 1995. Since the merger, accruals for the
reduction of 3,950 positions have been made. There have been no adjustments
made to increase or decrease amounts previously accrued for workforce reduction
or other restructuring activities.
Merger costs of $15,506 and $66,909 recorded in the third quarter and first
nine months of 1996, respectively, comprise certain nonrecurring organizational
costs, costs of establishing the corporate identity, and various other expenses
of a nonrecurring nature required to combine the two companies.
7
<PAGE> 8
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS:
FINANCIAL REVIEW
Overview of Consolidated Results
U.S. dollars in millions, except per-share data that are stated on a fully
diluted basis:
<TABLE>
<CAPTION>
Third Quarter Nine Months
-------------------------- --------------------------
Percent Percent
1996 Change 1995 1996 Change 1995
<S> <C> <C> <C> <C> <C> <C>
Total revenue $1,741.2 1.1% $1,721.5 $5,302.7 0.7% $5,268.3
Operating income 285.3 (8.9) 313.3 421.1 (56.2) 961.3
Net earnings 203.8 (11.7) 230.9 336.1 (52.0) 700.4
Fully diluted earnings
per common share $ 0.39 (11.4) $ 0.44 $ 0.64 (52.2) $ 1.34
</TABLE>
When comparing operating performance for the third quarter and first nine
months of 1996 to those periods in 1995, restructuring expenses, merger costs,
and non-recurring items should be considered. Restructuring and merger costs
associated with the November 1995 merger, totaling $52.8 million ($33.9 million
or $.06 per share after tax), were incurred in the third quarter of 1996,
compared to $1.9 million ($1.2 million after tax with nominal per share effect)
for 1995. Restructuring and merger costs for the first nine months of 1996
were $525.1 million ($330.9 million or $.63 per share after tax) compared to
$13.7 million ($9.8 million or $.02 per share after tax) in 1995.
Year-to-date results for 1996 also include a charge of $106.2 million ($69.1
million or $.13 per share after tax) to marketing, administrative and other
expense representing a write-down related to the impairment of an investment
related to the second quarter termination of an agreement to develop the
hemoglobin-based oxygen transport product, Hemopure. In the first quarter of
1995, the sale of the company's rights under a product co-marketing agreement
increased other operating revenue for that nine-month period by $42.0 million
($26.0 million or $.05 per share after tax).
The company's prior year results were derived from the separate financial
statements of Pharmacia AB and The Upjohn Company. These statements were
combined retroactively to reflect the merger that was consummated on November
2, 1995. Certain reclassifications have been made to prior-year amounts to
reflect the current year's presentation.
PRODUCT SALES
The table below provides a year-to-year comparison of consolidated net sales
by major therapeutic product group:
U.S. dollars in millions
8
<PAGE> 9
<TABLE>
<CAPTION>
Third Quarter Nine Months
---------------------------------- ----------------------------------
Percent Percent
1996 Change 1995 1996 Change 1995
-------- ------- -------- -------- ------- -------
<S> <C> <C> <C> <C> <C>
Infectious disease $ 117.7 (21.6)% $ 150.2 $ 409.2 (18.7)% $ 503.3
Metabolic disease 153.8 1.4 151.6 460.9 (2.8) 474.4
Critical care and
thrombosis 131.3 (9.4) 144.9 443.1 1.7 435.7
Central nervous system 143.6 (0.1) 143.8 417.7 (1.1) 422.4
Oncology 164.3 15.3 142.5 439.2 2.1 430.1
Women's health 143.2 4.5 137.0 408.5 2.0 400.3
Nutrition 68.2 (29.8) 97.1 286.3 (2.8) 294.5
Ophthalmology 77.8 16.3 66.9 209.6 (4.6) 219.7
Other prescription
pharmaceuticals 200.9 (3.2) 207.5 604.2 (2.5) 619.5
Consumer Healthcare 169.2 26.9 133.3 561.3 35.4 414.5
Animal Health 107.3 (2.3) 109.8 282.7 0.5 281.2
Chemical and Contract
Manufacturing 91.1 68.7 54.0 229.8 42.0 161.8
-------- ----- -------- -------- ----- --------
Total pharmaceuticals 1,568.4 1.9 1,538.6 4,752.5 2.0 4,657.4
Diagnostics 48.5 (11.5) 54.8 165.7 (14.9) 194.8
Biotech/Biacore 103.8 4.5 99.3 317.9 8.8 292.1
-------- ------ -------- -------- ----- --------
Consolidated net sales $1,720.7 1.7% $1,692.7 $5,236.1 1.8% $5,144.3
======== ====== ======== ======== ====== ========
</TABLE>
Sales outside the U.S. represented 66.0 percent of consolidated third-quarter
1996 sales and 67.7 percent for nine months compared to 68.9 percent and 69.4
percent, respectively in 1995. Changes in the geographic composition of sales
were as follows:
<TABLE>
<CAPTION>
Percent
1996 Change 1995
-------- ------- --------
<S> <C> <C> <C>
Third quarter sales
U.S. $ 585.2 11.1% $ 526.8
Non-U.S. 1,135.5 (2.6) 1,165.9
-------- --------
Consolidated $1,720.7 1.7% $1,692.7
-------- --------
Nine-months sales
U.S. $1,691.3 7.4% $1,574.1
Non-U.S. 3,544.8 (0.7) 3,570.2
-------- --------
Consolidated $5,236.1 1.8% $5,144.3
======== ========
</TABLE>
The 1.7 percent favorable consolidated sales comparison for the third quarter
of 1996 results from net increases in activity (price and volume effects)
despite the continuing effects of a biennial price decrease in Japan that
occurred in the second quarter and the continued generic competition in the
U.S. Sales activity increases for the quarter were partially offset by a two
9
<PAGE> 10
percent adverse effect from foreign exchange principally due to the weakened
Japanese yen.
The third-quarter sales decline in Infectious Disease products resulted from
decreases in all major product groups. Sales of the Cleocin (Dalacin outside
the U.S.) family of antibiotic products were down in non-U.S. markets. Sales
of Vantin, the broad-spectrum oral antibiotic sold primarily in the U.S.,
continued to decline due to competition from a new class of antibiotics,
Macrolides. For the first nine months of 1996, sales of Vantin also were
affected adversely by a relatively moderate cold and flu season. Mycobutin,
also a broad spectrum oral antibiotic, was down in both U.S. and non-U.S.
markets also due in part to competition from Macrolides. Mycobutin sales were
also adversely affected because the product cannot be used in HIV/AIDS patients
in association with some of the recently introduced protease inhibitors.
Products for the treatment of Metabolic Disease increased slightly for the
third quarter of 1996 led by moderate growth in Glynase sales in the U.S. due
to special promotions. Sales of Genotropin, the growth hormone, were down
slightly for the quarter due to adverse affects of foreign exchange and price
decreases in Japan. Genotropin continues to contribute strong volume growth in
Europe, especially in Italy, Germany, and Sweden. Volume increases in Japan
were offset by the continued effects of a second quarter government mandated
biennial price decrease. In spite of continuing U.S. generic competition for
Micronase tablets (glyburide), the oral anti-diabetes agent, significant
declines in sales experienced for the first nine months of 1996 slowed slightly
for the third quarter.
Sales growth in Critical Care and Thrombosis was led by Fragmin, the treatment
for prevention of blood clots in connection with surgery. Net sales of Fragmin
in Japan increased due to a restructuring of an existing distributor
relationship which has no impact on net earnings. Fragmin continues to
demonstrate good growth throughout Europe, especially Germany, Sweden, and
France. Sales of Solu-Medrol and other Medrol products were flat for the
quarter and down in year-to-date comparisons, mostly due to adverse foreign
exchange impacts and second quarter biennial price decreases in Japan. Sales
declines in Critical Care and Thrombosis during the quarter resulted
substantially from the transfer of certain products to the Chemical and
Contract Manufacturing group.
Sales of Central Nervous System agents for the third quarter were flat
compared to 1995. Third quarter 1996 sales of Xanax, the anti-anxiety agent,
recorded strong sales growth in the U.S. despite strong generic competition.
Xanax also was up moderately in Europe, mostly in Italy, and in Latin America.
Sales of Halcion Tablets, the sleep inducing agent, were up slightly in
non-U.S. markets offset by declines in U.S. sales. Sermion, the agent for the
treatment of senile dementia, declined in Japan due partially to adverse
foreign currency affects. Slight decreases were also experienced in other
non-U.S. locations.
The launch of Camptosar (irinotecan), for the treatment of refractory
colorectal cancer, in the U.S., was primarily responsible for the third quarter
growth in the oncology product group. Sales of oncology products also continue
to be led by Farmorubicin, the cytostatic agent for the treatment of solid
tumors and leukemia. Third quarter sales of Farmorubicin were up moderately.
This was largely due to increased sales volume in Japan despite
10
<PAGE> 11
unfavorable pricing pressure experienced for the first half of 1996. Sales of
Adriamycin, also a cytostatic agent for treatment of solid tumors and leukemia,
were down in the U.S. due to continued price erosion as a result of generic
competition. Non-U.S. sales of Adriamycin were down slightly, mostly in Latin
America. Other branded and generic oncology products recorded sales growth
outside the U.S.
In the Women's Health product group, sales growth in the third quarter was led
by U.S. sales of Ogen, the estrogen replacement therapy, due to enhanced sales
incentives. Sales of Depo-Provera, the injectable contraceptive, continued to
rise in the U.S. but fell in non-U.S. markets for the quarter. While U.S.
sales of Provera products (medroxyprogesterone), the progestational agents,
grew in the quarter as a result of September promotions, year-to-date sales
continued to decline worldwide due to increasing generic competition.
The decline in sales of Nutrition products resulted substantially from the
third quarter transfer of certain products to the Chemical and Contract
Manufacturing group. Sales gains for Intralipid, a fat emulsion for
intravenous nutrient delivery, in non-U.S. markets were offset by declines in
the U.S. Sales of other nutritional products for the nine-month period were
down due to weakening demand in Italy, Sweden, Spain and France.
The launch in the U.S., Sweden and Switzerland of Xalatan, an intraocular
pressure-lowering medication for the treatment of glaucoma, contributed to the
strong sales growth in Ophthalmology products in the third quarter. Sales of
Healon, a viscoelastic used in cataract surgery, grew in the U.S. but fell in
Japan and Europe due to increased competition. Japan sales were negatively
impacted by the weak yen and the biennial price reduction.
In Other Prescription Pharmaceutical products, sales of Salazopyrin, the
preparation used to treat inflammatory bowel disorder and rheumatoid arthritis,
were up. Strong sales gains were also made in the U.S. by Caverject, the
treatment for male impotence, first marketed in the third quarter of 1995,
while sales in non-U.S. markets were down slightly for the quarter. Other
products declined, including anti-inflammatory agents Ansaid and Motrin, which
continued to suffer from generic competition.
Consumer Healthcare product sales were up significantly due to the U.S.
over-the-counter (OTC) launch of the Nicotrol patch during the third quarter.
The Nicotrol patch is a treatment for smoking cessation and is marketed in the
U.S. by McNeil Consumer Products (McNeil). Recent launches of other smoking
cessation products in the Nicorette product line include Nicorette gum,
launched for OTC sales late in the first quarter of 1996, and Nicorette Nasal
Spray, launched in the second quarter of 1996 for prescription sales. Both
Nicorette gum (marketed by SmithKline Beecham) and Nicorette nasal spray
(marketed by McNeil) contributed good growth in the U.S. in the third quarter.
Non-U.S. sales of Nicorette products were also up for the quarter due to
launches of Nicorette gum for OTC sales in France (June 1996) and Nicorette
Inhaler for OTC sales in Denmark (late September 1996). Beginning this
quarter, all sales of Rogaine (Regaine outside the U.S.), the treatment for
hair loss, are classified under Consumer Healthcare for all comparative
periods. Third-quarter OTC sales of Rogaine 2% were down in the U.S. due to
the effect of generic competition and when compared to the large initial sales
to establish retail inventories in the first six months of 1996. The
year-to-date increase in the OTC sales of Rogaine 2% solution have greatly
exceeded
11
<PAGE> 12
the prior year prescription sales. The launch of Kao Lectrolyte, an
electrolyte replenishment product for children, in the U.S. during the third
quarter also contributed to overall growth in Consumer Healthcare.
Sales for the Animal Health product group were down slightly for the quarter.
Sales in the U.S. were down due to reductions in livestock herds and when
compared to a particularly strong third quarter in 1995 that benefited from a
change in distributor methodology. The reduction in U.S. sales was reflected in
all major product groups. Sales in non-U.S. markets were up slightly for the
quarter due to the September 1996 acquisition of Pherrovet AB, a leading animal
health company in the Nordic region.
The sales growth recorded by the Chemical and Contract Manufacturing group was
due primarily to the transfer of certain European products into this sales
classification for 1996 (reported in other prescription pharmaceutical
groupings in 1995). Sales of specialty and commodity steroid products were
down slightly in the third quarter.
Reduced sales in the Diagnostics business resulted from continued decline in
allergy diagnostic products due to milder pollen seasons in Japan and Europe.
In addition, sales in Japan were also negatively impacted by the weak yen while
sales in Europe were down due to changes in reimbursement policies in Germany,
France, and Switzerland.
The Biotech and Biacore (previously named Biosensor) group continued to record
strong sales growth in the U.S. Sales gains in non-U.S. markets were
negatively impacted by unfavorable foreign currency exchange fluctuations
resulting in flat comparisons for the third quarter. Biotech/Biacore develops,
manufactures, and markets systems, reagents, and chemicals for pharmaceutical
and biotechnology companies and academic research laboratories.
OTHER OPERATING REVENUE
Comparatively, other revenue is down for the third quarter as 1995 included
revenue from promotional services provided for Zovirax, a product of Glaxo
Wellcome. This agreement was terminated at the end of 1995. Exclusive of that
item, other revenue from co-marketing agreements is up for the third quarter of
1996, including revenue for the co-marketing of Luvox, a treatment for
Obsessive Compulsive Disorder (OCD), with Solvay. In the first quarter of
1995, the company sold rights under a product co-marketing agreement that added
$42 million to this revenue classification, contributing to the comparative
decline for the first nine months of 1996.
12
<PAGE> 13
COSTS AND EXPENSES
Consolidated operating expenses, stated as a percent of net sales, were as
follows:
<TABLE>
<CAPTION>
Third Quarter Nine Months
------------------- ---------------------
1996 1995 1996 1995
---- ---- ---- ----
<S> <C> <C> <C> <C>
Cost of products sold 31.0% 27.6%(1) 29.3% 28.3%(1)
Research and development 19.2 17.9 17.8 17.9
Marketing, administrative
and other 31.4 37.6 (1) 36.0 37.2 (1)
Restructuring charges 2.2 - 8.8 0.2
Merger costs 0.9 0.1 1.3 -
Operating income 16.6 18.5 (1) 8.0 18.7 (1)
</TABLE>
(1) Previously reported for the third quarter (first nine months) of 1995 as:
Cost of products sold - 29.2% (28.5%); Marketing, administrative and
other - 38.3% (37.3%); and Operating income - 16.2% (18.4%). Gains and
losses from currency exchange forward contracts relating to certain net
transaction and anticipated currency exchange exposures are now
classified with cost of products sold to more accurately match the losses
and gains on the instruments underlying the exposures. Formerly, these
gains and losses had been classified as either an element of nonoperating
income (expense) or with administrative expense, depending on the status
of the contract.
The third quarter of 1996 experienced an increase in cost of products sold as
a percent of sales reflecting unfavorable period-to-period comparisons in
product mix and foreign exchange impact. Sales growth was affected by a weaker
Japanese yen and the costs were affected by the strengthening of the Swedish
krona and Italian lira. Geographic shifts in sales growth to markets with
higher costs as a percent of sales has also occurred. Generic competition for
ethical pharmaceutical products continues to reduce gross margin as sales
growth is shifted to lower-margin products. The decline in gross margin was
further affected by comparisons from the company's currency hedging program
related to the anticipatory transactions. The company had experienced
favorable comparisons from these programs through the first six months of the
year which had partially mitigated the effects of generic competition and
product mix. Year-to-year comparisons of cost as a percent of sales also
declined as the third quarter of 1995 benefited from gains on anticipatory
currency transactions.
Research and development (R&D) spending showed an increase in the third
quarter of 1996 in both dollars and as a percent of sales. This was largely
attributable to a contractual obligation of $26.0 million ($16.9 million and
$.03 per share after tax) recognized in the third quarter for a co-development
agreement to acquire future rights to a product. During the third quarter, the
company filed new product filings for Reboxetine (Europe), for depression,
Cabaser (Japan) for Parkinson's Disease, and Farlutal (Europe) for cachexia.
For the first nine months of 1996, the company has filed 9 new product filings.
The significant decrease in marketing, administrative and other expense
13
<PAGE> 14
(S,G&A) for the third quarter, both in total and as a percent of sales,
resulted in part due to the gain on the sale of an equity interest and related
dissolution of a joint venture of $46.2 million ($33.3 million and $.06 per
share after tax). Partially offsetting this gain was the establishment of a
product liability provision of $15.0 million ($9.7 million and $.02 per share).
The nine-month comparison included the charge of $106.2 million in the second
quarter of 1996 related to a termination of a co-development agreement with the
Biopure Corporation referred to above. Excluding the effects of unusual items,
S,G&A expense was down for the quarter and on a year-to-date basis. Declines in
S,G&A as a percent of sales for both comparable periods resulted from
realization of cost reductions under the company's merger related restructuring
plan combined with certain administrative credits. Year-to-date 1996 savings
realized from cost reductions were partially offset by additional costs that
have been incurred to reorganize certain sales, marketing and administrative
operations.
In December 1995, a major merger-related restructuring plan was announced to
eliminate duplicate facilities and functions and to focus resources on the
objectives of the newly merged company. This plan will ultimately lead to the
reduction of approximately 4,100 positions worldwide and the closing or
combining of numerous subsidiary locations and manufacturing facilities (plant
rationalizations). In addition, steps are being taken to focus research and
development activities on the most promising projects of the two companies.
This should result in the reduction of total R&D projects by approximately 20
percent. Merger-related restructuring charges for the third quarter of 1996
totaled $37.3 million and were $458.2 million for the first nine months of
1996. These costs were in addition to the $91.6 million of merger-related
restructuring charges accrued during the fourth quarter of 1995. These charges
primarily reflect the planned and actual reduction of approximately 3,950
positions through September 30, 1996. The costs in 1995 resulted from accruals
for reduction of approximately 850 of these positions, elimination of duplicate
office facilities, and other exit costs. At the end of the third quarter of
1996, approximately 3,300 employees had left the company under this
restructuring program. It is expected that further restructuring charges
associated with plant rationalizations as a result of the merger will continue
into 1997. Cash spending in 1996 for merger-related restructuring totaled
approximately $300 million, with approximately $250 million remaining as
other current and non-current liabilities of the company. These remaining
reserves include certain accruals for pensions and other employee benefits that
will be expended over the next several years. Savings from the merger-related
restructuring activities will be realized in all major expense categories and
are expected to have an increasing effect on earnings as elements of the plan
are fully implemented. It is estimated that most elements of the restructuring
plan, exclusive of portions of the plant rationalizations, will be implemented
by 1997.
The merger costs recorded in 1996 consisted primarily of expenses related to
certain nonrecurring organizational activities, establishing the corporate
identity for the new company, and various other costs of combining the two
companies. Future merger costs are anticipated to decline substantially from
those recorded in prior periods.
NONOPERATING INCOME AND EXPENSE
The favorable interest income to interest expense relationship continued to
14
<PAGE> 15
contribute to third quarter 1996 earnings. Declines in both interest income
and interest expense recorded for both quarter and year to date are due to the
termination of certain borrowing arrangements in Italy and Japan. Interest
expense was also reduced for the quarter as the above repayment of short-term
debt occurred at the beginning of the quarter with offsetting additional
short-term borrowing not occurring until the end of the quarter. Interest
income further decreased for the quarter due to reductions in both short-term
and long-term investments.
INCOME TAXES
The estimated annual effective tax rate for 1996 is 33 percent compared to 35
percent for the year 1995. Excluding nonrecurring charges, the effective tax
rate for 1996 is estimated to be 35 percent, unchanged from the prior year.
FINANCIAL CONDITION
<TABLE>
<CAPTION>
September 30, December 31,
1996 1995
------------- ------------
<S> <C> <C>
Working capital (U.S. dollars in millions) $2,490.0 $2,333.7
Current ratio 1.90 1.88
Debt to total capitalization 19.0% 17.9%
</TABLE>
Working capital increased slightly due to an increase in cash and cash
equivalents and other current assets partially offset by a reduction in
short-term investments. These increases in cash and other current assets
result from additional short-term borrowings and reductions in short-term and
long-term investments. Current ratio is essentially unchanged from December
31, 1995. The ratio of debt to capitalization increased from the prior year
end due to net additional short-term borrowings during the third quarter with
only a slight change in shareholders' equity.
The company's net financial asset position, presented below, declined from
prior year end due to a reduction in total short-term and long-term investments
and net increases in short-term debt. These declines are partially offset by a
corresponding increase in cash and cash equivalents.
<TABLE>
<CAPTION>
September 30, December 31,
1996 1995
------------- ------------
<S> <C> <C>
Cash, equivalents and investments $2,416.2 $2,529.5
Short-term and long-term debt 1,507.5 1,394.7
------------- ---------
Net financial assets $ 908.7 $1,134.8
============= =========
</TABLE>
15
<PAGE> 16
Cash Flows
Net cash provided by operations for the first nine months of 1996 declined to
$543.7 million compared to $793.9 million for the first nine months of 1995.
This decrease was primarily due to the large cash expenditures required by the
merger-related restructuring and by other merger costs incurred for the first
nine months of 1996. Additional uses of cash since the end of the prior year
include increases in receivables, inventories, net deferred taxes and other
current assets partially offset by decreases in other non-current assets.
For investing purposes, the most significant use of cash resulted from the
acquisition of property, plant and equipment. Reductions in both short-term
and long-term investments provided cash to fund this capital spending,
dividends to shareholders, and the termination of certain borrowing
arrangements in Italy and Japan (see discussion below). Proceeds from the sale
of investments for 1996 include the sale of an equity interest in Huhtamaki
Oy and a related dissolution of a joint venture.
Financing activities continue to be a significant use of cash for payment of
dividends to shareholders. When compared to the prior year, dividends to
common shareholders rose due to the greater number of outstanding shares issued
to effect the merger and an effective increase in combined dividend rate per
share. For 1996, short-term borrowings exceeded payments of debt by
approximately $100.0 million. Cash proceeds from the issuance of treasury
stock were related to the employee option program and were primarily utilized
for the purchase of common shares to be issued upon future exercise of stock
options.
The company's future cash provided by operations and borrowing capacity are
expected to cover normal operating cash flow needs and planned capital
acquisitions for the foreseeable future.
The company utilizes derivative financial instruments in conjunction with its
currency exchange risk management programs. These programs employ
over-the-counter forward currency exchange contracts and purchased currency
options to hedge existing net transaction exposures and certain existing
obligations in several subsidiary locations. These exposures arise both from
intercompany and third-party transactions. Additionally, certain instruments
are utilized to protect the effects of foreign currency fluctuations on the
cash flows of specific anticipated transactions.
The transaction hedging activities seek to protect operating results and cash
flows from the potential adverse effects of currency exchange rate
fluctuations. This is done by offsetting the gains or losses on the underlying
exposures with losses and gains on the instruments utilized to create the
hedges. The hedging of anticipated transaction exposures is intended to
protect the cash flows of the company by offsetting the gains or losses on the
instruments with the losses and gains of the underlying anticipated cash flows.
Because forward contracts used to hedge anticipated transaction exposures are
marked-to-market each period, but the anticipated transactions have not been
recorded, the timing of recognition of the related gains and losses will not
match.
OTHER ITEMS
16
<PAGE> 17
Various suits and claims arising in the ordinary course of business, primarily
for personal injury and property damage alleged to have been caused by the use
of the company's products, are pending against the company and its
subsidiaries. The company is also involved in several administrative and
judicial proceedings relating to environmental concerns, including actions
brought by the U.S. Environmental Protection Agency and state environmental
agencies for remedial cleanup at approximately 50 sites and including site
clean-up at the company's discontinued industrial chemical operations. The
Company's estimate of the ultimate cost to be incurred in connection with these
environmental situations could change due to uncertainties at many sites with
respect to potential cleanup remedies, the estimated cost of cleanup, and the
company's ultimate share of a site's cost.
Based on information currently available and the company's experience with
lawsuits of the nature of those currently filed or anticipated to be filed
which have resulted from business activities to date, the amounts accrued for
product and environmental liabilities are considered to be adequate. Although
the company cannot predict and cannot make assurances with respect to the
outcome of individual lawsuits, the ultimate liability should not have a
material effect on its consolidated financial position; and unless there is a
significant deviation from the historical pattern of resolution of such issues,
the ultimate liability should not have a material adverse effect on the
company's results of operations or liquidity.
In May 1994, the U.S. Food and Drug Administration (FDA) established a Task
Force to review the FDA's prior inspection report on Halcion, including an
assessment of the conclusions of the report, the approval of the drug, related
FDA processes and procedures, and the violation of any laws. The U.S.
Attorney's Office in Grand Rapids, Michigan assisted in this review. Several
company employees have given testimony before a grand jury sitting in the U.S.
District Court for the Western District of Michigan, and a number of current
and former employees have been interviewed by FDA and Justice Department
investigators. The Task Force recently issued its report, which found no
evidence of criminal wrongdoing, but suggested that the Justice Department is
the appropriate entity to determine and evaluate the facts and to determine
whether criminal offenses had occurred and should be pursued. The Task Force
also concluded that the evidence supports the safety and efficacy of Halcion
tablets when used in accordance with its approved labeling. However, the Task
Force recommended that a wide spectrum of experts review the safety and
efficacy data on Halcion tablets, and report their findings to the FDA's
Psychopharmalogical Drugs Advisory Committee. The Task Force also recommended
several improvements in FDA practices and procedures. The company cannot
predict the outcome of any continuing investigation by the Justice Department
or the FDA. A subcommittee of the House of Representatives has instituted a
review of some of the conclusions of the original inspection report and is
reviewing the Task Force report. The company has furnished the subcommittee a
large number of documents in responding to the subcommittee's request. The
company cannot predict the nature, scope, or timing of any further review by
the subcommittee.
The company is a party along with a number of other defendants (both
manufacturers and wholesalers) in several federal civil antitrust lawsuits, some
of which have been consolidated and transferred to Federal District Court for
the Northern District of Illinois. These suits allege that the company and the
other named defendants violated: (1) the Robinson-Patman Act by giving
substantial discounts and rebates to mail-order pharmacies and managed health
care organizations without according the same discounts to retail pharmacies,
and (2) Section I of the Sherman Antitrust Act by entering into illegal
agreements to deny such discounts and rebates to retailers. The Federal
District Court for the Northern District of Illinois certified a national class
of retail pharmacies in November 1994. In July 1996, the Federal District
Court approved a settlement between a majority of the pharmaceutical company
defendants (not including the company) and the plaintiffs in the class action
pending in the Northern District of Illinois for amounts ranging from $10,000
to $60,000. The company together with the remaining settling and non-settling
defendants, are appealing to the United States Court of Appeals for the Seventh
Circuit from certain of the trial judge's orders. Actions raising claims
similar to the federal lawsuits have been brought on behalf of retail
drugstores and/or consumers in a number of state courts, including Alabama,
Arizona, California, Colorado, the District of Columbia, Maine, Michigan,
Minnesota, New York, Washington, and Wisconsin. The California State court has
certified both a retailer class and a consumer class, and the Wisconsin State
court has certified a retailer class. In March 1996, the Federal Trade
Commission ("FTC") issued a resolution authorizing an investigation to
determine whether 22 prescription drug manufacturers, including the Company,
are engaging in unlawful concerted activities to raise, fix, maintain or
stabilize the prices of pharmaceutical drugs in the United States. In July
1996, the FTC issued document subpoenas to each of the manufacturers,
requesting pricing and marketing documents. The Company has produced documents
to the FTC in response to the subpoena.
17
<PAGE> 18
FORWARD-LOOKING INFORMATION
Certain statements set forth above, such as statements concerning the company's
anticipated workforce reduction, reduction in R&D projects, timing of
merger-related cost savings and plant rationalizations, estimated annual
effective tax rate, adequacy of cash from operations, borrowing capacity, and
product and environmental liability reserves and other non-historical facts,
are "forward-looking statements" (as such term is defined in the Private
Securities Litigation Reform Act of 1995). Since these statements are based on
factors that involve risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such factors include, among others: management's ability to make further
progress under the company's merger integration plan; the company's ability to
successfully market new and existing products in new and existing domestic and
international markets; the success of the company's research and development
activities and the speed with which regulatory authorizations and product
rollouts may be achieved; fluctuations in foreign currency exchange rates; the
effects of the company's accounting policies and general changes in generally
accepted accounting practices; the company's exposure to product liability
lawsuits and contingencies related to actual or alleged environmental
contamination; domestic and foreign social, legal and political developments,
especially those relating to healthcare reform and product liabilities; general
economic and business conditions; the company's ability to attract and retain
current management and other employees of the company; and other risks and
factors detailed in the company's Securities and Exchange Commission filings,
including its Proxy Statement and Annual Report on Form 10-K for the year ended
December 31, 1995.
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K.
(a)(i) Exhibit A - Report of Independent Accountants (page
20).
(a)(ii) Exhibit 11 - Statement regarding computation of
earnings per share (page 21).
(a)(iii) Exhibit 12 - Ratio of Earnings to Fixed Charges (page
22).
(a)(iv) Exhibit 15 - Awareness of Coopers & Lybrand L.L.P.
(page 23).
(a)(v) Exhibit 27 - Financial Data Schedule (EDGAR filing
only).
(b) Form 8-K - On July 2, 1996, Form 8-K/A was filed
amending a June 18, 1996 filing by adding a letter from
KPMG Peat Marwick LLP wherein KPMG Peat Marwick LLP
affirmed the statements made in the June 18 filing.
The June 18 Form 8-K announced the action by the Board
of Directors to appoint Coopers & Lybrand L.L.P. as the
company's certifying accountants.
18
<PAGE> 19
SIGNATURE:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHARMACIA & UPJOHN, INC.
------------------------
(Registrant)
DATE: November 14, 1996 /S/R. C. SALISBURY
R. C. Salisbury
Executive Vice President,
Finance and Administration
and Chief Financial Officer
DATE: November 14, 1996 /S/K. M. Cyrus
K. M. Cyrus
Senior Vice President,
General Counsel and Secretary
19
<PAGE> 20
EXHIBIT
EXHIBIT A
INDEPENDENT ACCOUNTANT'S REPORT
To the Shareholders and
Board of Directors
Pharmacia & Upjohn, Inc.
We have reviewed the condensed consolidated balance sheet of Pharmacia &
Upjohn, Inc. and Subsidiaries as of September 30, 1996, and the related
condensed consolidated statements of earnings and cash flows for the three
and nine months then ended. These financial statements are the responsibility
of Pharmacia & Upjohn, Inc.'s management.
We conducted our review in accordance with standards established by the
American Institute of Certified Public Accountants. A review of interim
financial information consists principally of applying analytical procedures to
financial data and making inquiries of persons responsible for financial and
accounting matters. It is substantially less in scope that an audit conducted
in accordance with generally accepted auditing standards, the objective of
which is the expression of an opinion regarding the financial statements taken
as a whole. Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that
should be made to the accompanying condensed consolidated financial statements
referred to above, for them to be in conformity with generally accepted
accounting principles.
We have previously audited, in accordance with generally accepted auditing
standards, the consolidated balance sheet as of December 31, 1995, and the
related consolidated statements of earnings, shareholders' equity, and cash
flows for the year then ended (not presented herein); and in our report, dated
February 21, 1996, we expressed an unqualified opinion on those consolidated
financial statements. In our opinion, the information set forth in the
accompanying condensed consolidated balance sheet as of December 31, 1995, is
fairly stated, in all material respects, in relation to the consolidated
balance sheet from which it has been derived.
Coopers & Lybrand L.L.P.
Chicago, Illinois
October 31, 1996
20
<PAGE> 21
EXHIBIT INDEX
<TABLE>
<CAPTION>
SEQUENTIALLY
EXHIBIT NUMBERED
NUMBER DESCRIPTION PAGE
- ------- ----------- ------------
<S> <C> <C>
EX 11 Statement regarding computation of earnings per share
EX 12 Ratio of Earnings to Fixed Charges
EX 15 Awareness of Coopers & Lybrand L.L.P.
EX 27 Financial Data Schedule
</TABLE>
<PAGE> 1
EXHIBIT 11
PHARMACIA & UPJOHN, INC. AND SUBSIDIARIES
COMPUTATION OF EARNINGS PER COMMON SHARE - PRIMARY
(In millions, except per-share data)
<TABLE>
<CAPTION>
Three Months Nine Months
Ended September 30, Ended September 30,
1996 1995 1996 1995
------ ------ ------ ------
<S> <C> <C> <C> <C>
Net earnings $203.8 $230.9 $336.1 $700.5
Dividends on preferred stock, net of tax 3.2 3.1 9.5 9.3
------ ------ ------ ------
Net earnings on common shares - primary $200.6 $227.8 $326.6 $691.2
====== ====== ====== ======
Average number of common shares outstanding 508.6 503.9 508.4 504.4
Number of common shares issuable assuming
exercise of stock options 4.1 3.1 3.9 1.7
Contingently issuable incentive common shares .5 .5 .5 .5
----- ----- ----- -----
Total shares - primary 513.2 507.5 512.8 506.6
===== ===== ===== =====
Primary earnings per common share $. 39 $ .45 $ .64 $ 1.36
====== ====== ====== ======
</TABLE>
COMPUTATION OF EARNINGS PER COMMON SHARE - FULLY DILUTED(1)
<TABLE>
<S> <C> <C> <C> <C>
Net earnings $203.8 $230.9 $336.1 $700.5
Less ESOP contribution assumed to be required
if preferred shares are converted into common
shares 1.0 1.1 3.1 3.5
Less tax benefit of preferred stock dividend on
allocated shares .4 .3 1.0 .8
Plus tax benefit assumed on common stock dividend .2 .1 .6 .5
------ ------ ------ ------
Net earnings on common shares - fully diluted $202.6 $229.6 $332.6 $696.7
====== ====== ====== ======
Average number of common shares outstanding 508.6 503.9 508.4 504.4
Number of common shares issuable assuming
exercise of stock options 4.1 3.3 3.9 3.3
Contingently issuable incentive common shares .5 .5 .5 1.1
Number of common shares issuable assuming
conversion of preferred shares 10.3 10.5 10.4 10.5
----- ----- ----- -----
Total shares - fully diluted 523.5 518.2 523.2 519.3
====== ====== ====== ======
Fully diluted earnings per common share $.39 $.44 $.64 $1.34
==== ==== ==== =====
</TABLE>
(1) This calculation is submitted in accordance with the regulations of the
Securities and Exchange Commission although not required by APB Opinion No. 15
because it results in dilution of less than 3%.
21
<PAGE> 1
EXHIBIT 12
PHARMACIA & UPJOHN, INC. AND CONSOLIDATED SUBSIDIARIES
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
<TABLE>
<CAPTION>
Nine Months Year Ended December 31,
Ended ------- -------- -------
30-Sep-96 1995 1994 1993
--------- -------- -------- --------
<S> <C> <C> <C> <C>
Earnings from continuing operations before income taxes $501,612 $1,136,393 $1,271,276 $ 777,736
Less: Equity in undistributed net income (loss) of companies
owned less than 50% 2,655 7,389 8,156 8,037
-------- ---------- ---------- ----------
498,957 $1,129,004 1,263,120 769,699
Add: Amortization of previously capitalized interest 7,308 10,079 7,695 5,419
Fixed charges included in the above:
Interest and amortization of debt expense 70,995 121,018 139,013 209,399
Rental expense representative of an interest factor 26,497 35,330 35,290 32,348
-------- ---------- ---------- ----------
Earnings from continuing operations before income taxes
and fixed charges $603,757 $1,295,431 $1,445,118 $1,016,865
======== ========== ========== ==========
Interest incurred and amortization of debt expense $ 90,805 $ 148,542 $ 164,341 $ 233,683
Rental expense representative of an interest factor 26,497 35,330 35,290 32,348
-------- ---------- ---------- ----------
Total fixed charges $117,302 $ 183,872 $ 199,631 $ 266,031
======== ========== ========== ==========
Ratio of earnings to fixed charges 5.15 7.05 7.24 3.82
======== ========== ========== ===========
</TABLE>
<TABLE>
<CAPTION>
Year Ended December 31,
-------- ------
1992 1991
-------- ------
<S> <C> <C>
Earnings from continuing operations before income taxes $ 947,395 $ 909,659
Less: Equity in undistributed net income (loss) of companies
owned less than 50% 6,464 5,062
---------- ----------
940,931 904,597
Add: Amortization of previously capitalized interest 4,486 3,109
Fixed charges included in the above:
Interest and amortization of debt expense 162,425 145,655
Rental expense representative of an interest factor 34,743 36,834
---------- ----------
Earnings from continuing operations before income taxes
and fixed charges $1,142,585 $1,090,195
========== ==========
Interest incurred and amortization of debt expense $ 178,677 $ 158,724
Rental expense representative of an interest factor 34,743 36,834
---------- ----------
Total fixed charges $ 213,420 $ 195,558
========== ==========
Ratio of earnings to fixed charges 5.35 5.57
========== ==========
</TABLE>
22
<PAGE> 1
EXHIBIT 15
Securities & Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
RE: Pharmacia & Upjohn, Inc.
Registration on Form 10-Q
We are aware that our report dated October 31, 1996 on our review of interim
financial information of Pharmacia & Upjohn, Inc. and Subsidiaries for the
three and nine month periods ended September 30, 1996 and 1995, included in
this Form 10-Q is incorporated by reference in the Company's prospectus in Form
S-8 Registration Statement (No. 33-63903) and the prospectus in Form S-8
Registration Statement (No. 33-03109) and the prospectus in Form S-3
Registation Statement (No. 33-06045). Pursuant to Rule 436(c) under the
Securities Act of 1933, this report should not be considered a part of the
registration statements prepared or certified by us within the meaning of
Sections 7 and 11 of the Act.
Coopers & Lybrand L.L.P.
Chicago, Illinois
November 13, 1996
23
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-01-1996
<PERIOD-END> SEP-30-1996
<CASH> 1,092,077
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 1,019,624
<CURRENT-ASSETS> 5,242,572
<PP&E> 0
<DEPRECIATION> 0
<TOTAL-ASSETS> 11,527,712
<CURRENT-LIABILITIES> 2,752,570
<BONDS> 829,731
0
287,117
<COMMON> 5,087
<OTHER-SE> 6,121,584
<TOTAL-LIABILITY-AND-EQUITY> 11,527,712
<SALES> 5,236,116
<TOTAL-REVENUES> 5,302,654
<CGS> 1,536,480
<TOTAL-COSTS> 1,536,480
<OTHER-EXPENSES> 932,695<F1>
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 51,315
<INCOME-PRETAX> 501,612
<INCOME-TAX> 165,500
<INCOME-CONTINUING> 336,112
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 336,112
<EPS-PRIMARY> .64
<EPS-DILUTED> .64
<FN>
<F1>INCLUDES R&D ONLY
</FN>
</TABLE>
